ArticleMolecules (Basel, Switzerland)2022
Hyaluronic Acid Modified Nanostructured Lipid Carrier for Targeting Delivery of Kaempferol to NSCLC: Preparation, Optimization, Characterization, and Performance Evaluation In Vitro.
Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- Article
- Cellular reprogramming and signaling control by kaempferol in colorectal cancer.Discover oncology · 2026Review
- Article
- Emerging Role of Nanostructured Lipid Carriers in Overcoming Cancer Treatment Challenges.Pharmaceutical research · 2026Review
- Kaempferol-based nanocarriers as a potential therapeutic strategy against drug-resistant lung cancer.Cancer cell international · 2026Review
- DualAntioxidants (Basel, Switzerland) · 2026Article
- Design Evolution of Curcumin-Loaded Nanostructured Lipid Carriers: Formulation Strategies, Functional Modifications, and Mechanistic-Translational Perspectives.International journal of nanomedicine · 2026Review
- The Supportive Role of Plant-Based Substances in AMD Treatment and Their Potential.International journal of molecular sciences · 2025Review
- Emerging Nanoparticle-Based Diagnostics and Therapeutics for Cancer: Innovations and Challenges.Pharmaceutics · 2025Review
- Hybrid Carbohydrate-Lipid Nanocarriers: In Vitro Efficacy Gene-Rated by Association of UV-Absorbers and Raspberry Polyphenols Rich-Fraction.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Correction: Ma et al. Hyaluronic Acid Modified Nanostructured Lipid Carrier for Targeting Delivery of Kaempferol to NSCLC: Preparation, Optimization, Characterization, and Performance Evaluation In Vitro.Molecules (Basel, Switzerland) · 2024Article
- The Anticancer Potential of Kaempferol: A Systematic Review Based on In Vitro Studies.Cancers · 2024Review
- Recent Advances in Nanotechnology-Based Targeted Delivery Systems of Active Constituents in Natural Medicines for Cancer Treatment.Molecules (Basel, Switzerland) · 2023Review
- Preparation, characterization, and evaluation of the antitumor effect of kaempferol nanosuspensions.Drug delivery and translational research · 2023Article
- Hyaluronic Acid-Mediated Phenolic Compound Nanodelivery for Cancer Therapy.Pharmaceutics · 2023Review
- Exploiting Polyphenol-Mediated Redox Reorientation in Cancer Therapy.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Article
- Pimozide-loaded nanostructured lipid carriers: Repurposing strategy against lung cancer.Science progressArticle
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Lung cancer seriously threatens the health of human beings, with non-small cell lung cancer (NSCLC) accounting for 80%. Nowadays, the potential position of nano-delivery in treating cancer has been the subject of continuous research. The present research aimed to prepare two molecular weight hyaluronic acid (HA)-modified kaempferol (KA)-loaded nanostructured lipid carriers (HA-KA-NLCs) by the method of melting ultrasonic and electrostatic adsorption, and to assess the antitumor effect of the preparations on A549 cells. The characterization and safety evaluation of the preparations illustrated that they are acceptable for drug delivery for cancer. Subsequently, differential scanning calorimetry (DSC) curve and transmission electron microscopy (TEM) images indicated that the drug was adequately incorporated in the carrier, and the particle appeared as a sphere. Moreover, HA-KA-NLC showed predominant in vitro antitumor effects, inhibiting proliferation, migration, and invasion, promoting apoptosis and increasing cellular uptake of A549 cells. Otherwise, the Western blot assay revealed that preparations could activate epithelial-mesenchymal transition (EMT)-related signaling pathways and modulate the expression of E-cadherin, N-cadherin, and Vimentin in A549 cells. Our present findings demonstrated that HA-KA-NLC could be considered as a secure and effective carrier for targeted tumor delivery and may have potential application prospects in future clinic therapy of NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.